---
title: "Junshi Biosciences Board Approves 2026 Q1 Report at Fully Attended Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284233708.md"
description: "Shanghai Junshi Biosciences Co., Ltd. announced that its board approved the 2026 Q1 report during a fully attended meeting on April 27, 2026. The meeting confirmed compliance with listing rules and highlighted the company's governance framework. All 14 eligible directors participated, and the report was endorsed by the audit committee. The latest analyst rating for the stock (HK:1877) is a Hold with a price target of HK$34.70. The company focuses on innovative medicines in oncology and immunology, with a market cap of HK$41.62B."
datetime: "2026-04-27T14:14:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284233708.md)
  - [en](https://longbridge.com/en/news/284233708.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284233708.md)
---

# Junshi Biosciences Board Approves 2026 Q1 Report at Fully Attended Meeting

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an update.

Shanghai Junshi Biosciences Co., Ltd. has disclosed an overseas regulatory announcement in Hong Kong, aligning its Hong Kong disclosure with information released on the Shanghai Stock Exchange. The notice reiterates the company’s compliance with listing rules and outlines the current composition of its board, underscoring a robust governance framework.

The board held the nineteenth meeting of its fourth session on 27 April 2026, with all 14 eligible directors attending and procedures confirmed as lawful and valid. At the meeting, directors reviewed and approved the company’s first quarterly report for 2026, following prior endorsement by the audit committee, signaling continued regulatory compliance and structured financial oversight for stakeholders.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

**More about Shanghai Junshi Biosciences Co., Ltd. Class H**

Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong and Shanghai. The company focuses on research, development and commercialization of innovative medicines, particularly in oncology and immunology, targeting both domestic and international healthcare markets.

**Average Trading Volume:** 3,924,048

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** HK$41.62B

For an in-depth examination of 1877 stock, go to TipRanks’ Overview page.

### Related Stocks

- [01877.HK](https://longbridge.com/en/quote/01877.HK.md)
- [688180.CN](https://longbridge.com/en/quote/688180.CN.md)

## Related News & Research

- [Shanghai Junshi Biosciences Sets Board Meeting to Approve Q1 2026 Results](https://longbridge.com/en/news/282830459.md)
- [Junshi Biosciences Shareholder Plans Up to 2% Stake Reduction](https://longbridge.com/en/news/283841816.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [China XLX Announces 2026 Q1 Results | CXLFF Stock News](https://longbridge.com/en/news/286673637.md)
- [Crombie Reit Announces May 2026 Monthly Distribution | CROMF Stock News](https://longbridge.com/en/news/286603129.md)